METASTATIC CASTRATION SENSITIVE PROSTATE CANCER (MCSPC)
Clinical trials for METASTATIC CASTRATION SENSITIVE PROSTATE CANCER (MCSPC) explained in plain language.
Never miss a new study
Get alerted when new METASTATIC CASTRATION SENSITIVE PROSTATE CANCER (MCSPC) trials appear
Sign up with your email to follow new studies for METASTATIC CASTRATION SENSITIVE PROSTATE CANCER (MCSPC), keep track of the ones that matter, and come back to a personal dashboard instead of checking manually.
Genom att skicka in godkänner du våra Användarvillkor
-
Real-world study tracks how long men stay on prostate cancer treatments
Knowledge-focused CompletedThis study reviewed medical records from cancer clinics to see how long men with metastatic prostate cancer that still responds to hormone therapy take two common drugs, apalutamide and enzalutamide. It included about 1,300 men aged 18 and older who started one of these drugs as …
Matched conditions: METASTATIC CASTRATION SENSITIVE PROSTATE CANCER (MCSPC)
Sponsor: Pfizer • Aim: Knowledge-focused
Last updated May 26, 2026 04:38 UTC
-
Finnish prostate cancer study reveals treatment patterns and outcomes
Knowledge-focused CompletedThis study looked at over 1,000 men in Finland with metastatic prostate cancer to understand their health, treatments, and how the disease progresses. Researchers collected information from medical records to see what treatments were used and how well they worked. The goal was to…
Matched conditions: METASTATIC CASTRATION SENSITIVE PROSTATE CANCER (MCSPC)
Sponsor: Pfizer • Aim: Knowledge-focused
Last updated May 22, 2026 13:54 UTC